Business StrategyPCVX provided positive business updates, including taking steps to increase the odds of delivering compelling VAX-31 Ph2 infant results by adding a new optimized dose.
Financial PositionAs of June 30, 2025, the company held $2.8B in cash, cash equivalents, and investments, which management now expects to fund operations through mid-2028.
Market PotentialVAX-31 in adults should lead to robust immunogenicity and protection, resulting in a large market.